Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to -$30.8 million.

  • Editas Medicine's Cash from Operations rose 4134.97% to -$30.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$179.6 million, marking a year-over-year increase of 118.07%. This contributed to the annual value of -$210.3 million for FY2024, which is 5909.15% down from last year.
  • Per Editas Medicine's latest filing, its Cash from Operations stood at -$30.8 million for Q3 2025, which was up 4134.97% from -$50.2 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Cash from Operations ranged from a high of -$22.2 million in Q4 2023 and a low of -$57.1 million during Q2 2024
  • Over the past 5 years, Editas Medicine's median Cash from Operations value was -$42.3 million (recorded in 2022), while the average stood at -$42.8 million.
  • In the last 5 years, Editas Medicine's Cash from Operations surged by 4738.96% in 2023 and then crashed by 12824.64% in 2024.
  • Quarter analysis of 5 years shows Editas Medicine's Cash from Operations stood at -$34.6 million in 2021, then decreased by 22.24% to -$42.3 million in 2022, then soared by 47.39% to -$22.2 million in 2023, then plummeted by 128.25% to -$50.8 million in 2024, then skyrocketed by 39.24% to -$30.8 million in 2025.
  • Its last three reported values are -$30.8 million in Q3 2025, -$50.2 million for Q2 2025, and -$47.8 million during Q1 2025.